ION BLUE

ION BLUE RESEARCH

Peptide Encyclopedia

Watchlist

Searched, not yet evidenced

These compounds are frequently searched or discussed online. Listing here is not an endorsement and does not indicate evidence of safety or effectiveness. Most lack published independent human research.

21 compounds tracked for transparency. See validated entries.

Cosmetic ingredients

  • Palmitoyl Tripeptide-5No verifiable independent human evidence identified

    Also known as: INCI Palmitoyl Tripeptide-5

    Regulatory (as of Jun 2026): Cosmetic ingredient; regulated as a cosmetic, not an FDA-approved drug.

    Context: discussed in cosmetic and skincare formulation contexts.

  • Hexapeptide-9No verifiable independent human evidence identified

    Also known as: INCI Hexapeptide-9

    Regulatory (as of Jun 2026): Cosmetic ingredient; regulated as a cosmetic, not an FDA-approved drug.

    Context: discussed in cosmetic and skincare formulation contexts.

  • Hexapeptide-11No verifiable independent human evidence identified

    Also known as: INCI Hexapeptide-11 (distinct from the unrelated FOXO4-DRI research peptide)

    Regulatory (as of Jun 2026): Cosmetic ingredient; regulated as a cosmetic, not an FDA-approved drug.

    Context: discussed in cosmetic and skincare formulation contexts.

  • Tetrapeptide-21No verifiable independent human evidence identified

    Also known as: INCI Tetrapeptide-21 (GEKG)

    Regulatory (as of Jun 2026): Cosmetic ingredient; regulated as a cosmetic, not an FDA-approved drug.

    Context: discussed in cosmetic and skincare formulation contexts.

  • Acetyl Tetrapeptide-5No verifiable independent human evidence identified

    Also known as: INCI Acetyl Tetrapeptide-5

    Regulatory (as of Jun 2026): Cosmetic ingredient; regulated as a cosmetic, not an FDA-approved drug.

    Context: discussed in cosmetic and skincare formulation contexts.

Growth-hormone–axis peptides

  • HexarelinLimited independent human research identified

    Also known as: Examorelin

    Regulatory (as of Jun 2026): Not FDA-approved; prohibited in sport by WADA (growth-hormone-releasing peptide, category S2).

    Context: discussed in growth-hormone research contexts.

  • TesamorelinFDA-approved for a specific medical indication; independent research on broader use is limited

    Also known as: Egrifta, TH9507

    Regulatory (as of Jun 2026): FDA-approved prescription drug (Egrifta) for a specific medical indication; prohibited in sport by WADA (GHRH analogue, category S2). Cross-referenced to ION BLUE prescription/Path-2 scope.

    Context: discussed in growth-hormone and metabolic research contexts.

  • AOD-9604Limited independent human research identified (including trials that did not meet their endpoints)

    Also known as: AOD9604, hGH fragment 176-191

    Regulatory (as of Jun 2026): Not an FDA-approved drug; prohibited in sport by WADA (growth-hormone fragment, category S2).

    Context: discussed in growth-hormone and metabolic research contexts.

  • FollistatinPreclinical or animal data only; no verifiable independent human evidence identified

    Also known as: FST, FS-344

    Regulatory (as of Jun 2026): Not an FDA-approved drug; prohibited in sport by WADA (myostatin-affecting agent, category S4).

    Context: discussed in muscle and myostatin research contexts.

Melanocortin peptides

  • Melanotan ISold as a research chemical with no verifiable independent human evidence; a related compound (afamelanotide) carries approval for a specific rare condition

    Also known as: Afamelanotide, Melanotan-1, [Nle4-D-Phe7]-alpha-MSH

    Regulatory (as of Jun 2026): Material sold as "Melanotan I" is not an FDA-approved product; the afamelanotide form (Scenesse) carries regulatory approval for a specific rare condition.

    Context: discussed in skin-pigmentation research contexts.

  • PT-141FDA-approved for a specific medical indication; independent research on broader use is limited

    Also known as: Bremelanotide, Vyleesi

    Regulatory (as of Jun 2026): FDA-approved as a prescription drug (Vyleesi / bremelanotide) for a specific medical indication; research-chemical "PT-141" falls outside that approval.

    Context: discussed in sexual-health research contexts.

Neuro & longevity research peptides

  • EpitalonPreclinical or animal data only; no verifiable independent human evidence identified

    Also known as: Epithalon, Epithalone, AEDG peptide

    Regulatory (as of Jun 2026): Not FDA-approved; subject to change pending the July 2026 PCAC compounding review.

    Context: discussed in longevity and aging-research contexts.

  • SelankPreclinical or animal data only; no verifiable independent human evidence identified

    Also known as: TP-7

    Regulatory (as of Jun 2026): Not FDA-approved; sold as a research chemical.

    Context: discussed in neuropeptide and anxiety-research contexts.

  • SemaxPreclinical or animal data only; no verifiable independent human evidence identified

    Also known as: ACTH(4-7) analogue

    Regulatory (as of Jun 2026): Not FDA-approved (sold as a research chemical); subject to change pending the July 2026 PCAC compounding review.

    Context: discussed in neuropeptide and cognitive-research contexts.

  • DSIPPreclinical or animal data only; no verifiable independent human evidence identified

    Also known as: Emideltide

    Regulatory (as of Jun 2026): Not FDA-approved; subject to change pending the July 2026 PCAC compounding review.

    Context: discussed in sleep-research contexts.

Metabolic & mitochondrial

  • TesofensineLimited independent human research identified (investigational)

    Also known as: NS2330

    Regulatory (as of Jun 2026): Not FDA-approved (investigational).

    Context: discussed in metabolic-research contexts.

  • MOTS-cPreclinical or animal data only; no verifiable independent human evidence identified

    Also known as: Mitochondrial-derived peptide

    Regulatory (as of Jun 2026): Not FDA-approved; prohibited in sport by WADA (metabolic modulators, category S4).

    Context: discussed in mitochondrial and longevity research contexts.

  • NAD+ peptidesLoosely-defined product category; no verifiable independent human evidence identified for peptide-specific products

    Also known as: NAD+, nicotinamide adenine dinucleotide products

    Regulatory (as of Jun 2026): Marketed as dietary supplements; not FDA-approved drugs.

    Context: discussed in longevity and cellular-energy research contexts.

Reproductive-endocrine

  • KisspeptinLimited independent human research identified (investigational; in clinical trials)

    Also known as: Kisspeptin-10, metastin

    Regulatory (as of Jun 2026): Not FDA-approved (investigational); prohibited in sport by WADA (peptide-hormone agonist, category S2).

    Context: discussed in reproductive-endocrinology research contexts.

  • GonadorelinPreviously FDA-approved in the U.S.; current U.S. marketing status uncertain (see Regulatory); independent human research on broader use is limited

    Also known as: GnRH, LHRH, Factrel, Lutrepulse

    Regulatory (as of Jun 2026): As of June 2026, no FDA-approved gonadorelin product appears to be marketed in the U.S. per FDA/DailyMed (the branded product Factrel was withdrawn); confirm against current FDA records. GnRH analogues are addressed under WADA (category S2); status may depend on context.

    Context: discussed in reproductive-endocrinology research contexts.

Immune

  • Thymosin Alpha-1Approved in some countries (not the U.S.) for specific indications; independent human research on other use is limited

    Also known as: Thymalfasin, Zadaxin, Talpha1

    Regulatory (as of Jun 2026): Not FDA-approved in the U.S.; approved in some other countries (marketed as Zadaxin).

    Context: discussed in immune-research contexts.